Novovax Covid-19 vaccine gets emergency use nod for those aged between 12-18 years in India

Novavax has announced the first emergency use authorization for its Coovid-19 vaccine for adolescents falling in the age bracket of 12-18 years in India. According to an official statement released by Novovax, the vaccine, also known as NVX-CoV2373, is manufactured and marketed in India by the Serum Institute of India (SII) under the brand name Covovax and is the first protein-based vaccine authorized for use in this age group in India.

Advertisment

1/38

2/38

3/38

4/38

5/38

6/38

7/38

8/38

9/38

10/38

11/38

12/38

13/38

14/38

15/38

16/38

17/38

18/38

19/38

20/38

21/38

22/38

23/38

24/38

25/38

26/38

27/38

28/38

29/38

30/38

31/38

32/38

33/38

34/38

35/38

36/38

37/38

38/38

The Drugs Controller General of India (DCGI) has issued permission for restricted use in an emergency situation for Covovax for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 12 years of age and older.

"We`re proud of this first approval in adolescents given the efficacy and safety that our data show in this population and that our COVID-19 vaccine will provide an alternative protein-based vaccine option for individuals 12 years of age and older in India," said Stanley C Erck, President and Chief Executive Officer, Novavax.

In addition, Covovax has also received Emergency Use Listing (EUL) from the World Health Organization.